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Abstract Based on an original dataset, we analyze empirically the de-
terminants of ﬁrm growth in the French biotech industry during two periods,
1996-1999 and 1999-2002. We have two main results. First, Gibrat’s law is
violated. The growth of annual turnover is inﬂuenced by the initial size of the
ﬁrm. The eﬀect is non-linear, negative for small ﬁrms. Second, location has a
signiﬁcant impact on growth. We use diﬀerent sets of dummies to characterize
location and diﬀerent measures of ﬁrm growth. As a whole, our results point at
Marseilles (and its region) and Nanterre (but not Paris and Evry) as favorable
places for the growth of ﬁrms between 1999 and 2002. For the 1996-1999, the fa-
vorable places are Strasbourg (and Alsace) and Rhône-Alpes (Lyon/Grenoble).
O u ra n a l y s i st h u ss u g g e s t st h a tt h ec h a n ges in the (notably legal) environment
of French biotech ﬁrms that took place in 1999 had a drastic eﬀect on the
comparative advantages of locations for biotech ﬁrms.
Keywords Biotechnology, Industrial clustering, Firm growth.
JEL Codes L25, L65, R30.
1I n t r o d u c t i o n
Despite the importance of the issue, the empirical literature on ﬁrms’ growth
in high tech sectors is quite small. Indeed, most of the literature on high-tech
ﬁrms explores questions that are related to this one, but diﬀerent. For exam-
ple, Prevezer (1995) analyzes the growth of clusters of biotech ﬁrms, not of the
ﬁrms themselves.1 Since the growth of a cluster is measured by the number of
ﬁrms entering the cluster each year, it is related to the creation of new ﬁrms
∗Corresponding author GAEL, UMR INRA-Université Pierre Mendès-France, BP 47,
38040 Grenoble Cedex 9, France. E-mail: eric.avenel@upmf-grenoble.fr
†GAEL, UMR INRA-Université Pierre Mendès-France.
‡Grenoble Ecole de Management - DFR Marketing, Europole - 12, rue Pierre Sémard, BP
127, 38003 Grenoble cedex 01, France.
§GAEL, UMR INRA-Université Pierre Mendès-France.
1For other contributions along this line, see e.g. Baik and Folta (2001) and Swann, Prevezer
and Stout (1998).
1rather than to the growth of existing ﬁrms. In general, there is much more
work on ﬁrms’ creation than on ﬁrms’ growth in high-tech sectors. These pa-
pers provide valuable insight for the analysis of ﬁrms’ growth, but it is certainly
recommendable to be cautious when extrapolating the results on creation to
the analysis of growth. For example, Prevezer and Swann (1996) analyze both
the creation and the growth of biotech ﬁrms (measured by employment) and
show that the determinants of creation and growth are quite diﬀerent. While
the creation of biotech ﬁr m si nac l u s t e ri sf o s t e r e db yt h el e v e lo fe m p l o y m e n t
in the science base and the ﬁrms in other biotech sectors, growth is promoted
by the employment in the ﬁrms in the same biotech sector.2 Furthermore, most
of the studies exploring post-creation performances of individual ﬁrms explore
dimensions of ﬁrms’ performances other than the growth of turnover or employ-
ment. Aharonson et al. (2004), e.g., analyzes the impact of location on ﬁrms’
inventiveness. Zucker, Darby and Armstrong (2002) analyzes the inﬂuence of
the links between scientists and ﬁrms on ﬁrms’ innovative performances in the
biotech industry.3 Gilbert, Audretsch and McDougall (2004) provides an ex-
tensive review of this (mainly managerial) literature. In this paper, we focus
on the growth of ﬁrms’ turnover. This is because what we are interested in is
whether and how the biotech industry can bring products and services to the
market and create value by selling them. There is no guarantee that results ob-
tained for various measures of performance are valid when analyzing the growth
of turnover. This being said, we recall the main results from previous work on
the biotech industry.
Powell et al. (1996) and Baum et al. (2000) point at the role of alliances as
determinants of the performances of biotech ﬁrms. Powell et al. (1996) show
that alliances have a positive impact on the growth of biotech ﬁrms’ employ-
ment. They see alliances as a major vehicle of knowledge ﬂows and insist on the
importance of ﬁrms’ centrality in networks of learning. Niosi (2003) challenges
this view in two ways. Firstly, he shows that there are other determinants of
(fast) growth that are as crucial as alliances, namely access to venture capital
and exports.4 Secondly, he claims that alliances are not necessarily successes,
in particular when they are formed too early or too late. He also insists on the
necessity to distinguish between the many types of alliances that biotech ﬁrms
can build (with universities, other biotech ﬁrms, big pharmas, ...). Audretsch
and Feldman (2003) also underline the fact that biotech ﬁrms may well form
alliances simply because of a lack of resources and that this may well not be
2This can be interpreted as a demand side eﬀect: ﬁrms’ growth beneﬁts from sectorial
(inter-industry) demand and information externalities which reduce search costs for users.
3They show that coauthorship between ﬁrms scientists and university scientists, in partic-
ular star scientists, increases the patenting performances of ﬁrms. See below the discussion
of the role of science in ﬁrms’ performances. The authors also analyze the impact of coau-
thorship on products and employment, but due to multicollinearity problems, the results are
not reliable. The article includes historical perspectives on the industry and a review of the
literature on science-ﬁrms links in the sector.
4Niosi (2003) considers Canadian ﬁrms. This is probably why exports (to the US market)
are so important.
2optimal in terms of the long term development of the industry.5 They claim
that internal growth, in particular the vertical integration of production stages
in medical biotechs, may be a better way to follow. On the same point, Feld-
man and Ronzio (2001) report the results of a survey showing that 80% of the
surveyed biotech ﬁrms would like to integrate vertically into manufacturing.
They suggest that vertical integrationw i l ld e v e l o pi nt h eb i o t e c hs e c t o ra n d
that the "virtual ﬁrm" model defended by Powell et al. (1996) may well be
transitory.6 There is another point on which divergent views expressed in the
literature, namely the importance of geographic proximity in alliances between
dedicated biotech ﬁrms and their big industrial clients, notably pharmaceuti-
cal ﬁrms. While Prevezer (2001) suggests that the diﬃculties of British biotech
ﬁrms to form links with big local players explain part of the existing gap between
the British and US industries, Zeller (2001) claims that it is not a problem for
biotech ﬁrms specialized in research in the medical sector to form alliances with
pharmaceutical ﬁrms around the world. The issue is in fact not whether collo-
cation is important in industrial alliances, but whether it is more important in
these alliances than in others. Prevezer and Swann (1996) point at the fact that
biotech clusters formed around universities rather than around big industrial
players, suggesting that these ﬁrms are not key elements of the environment
for biotech ﬁrms. Audretsch and Feldman (2003) and Feldman (2003) claim
that while this holds for the early stages of development of the industry, big
ﬁrms may play a crucial role at later stages, because they are able to anchor a
developing industry in a location.7 For the period we consider, it is probably
too early for anchor ﬁrms to play a signiﬁcant role in the French biotech sector,
even if this hypothesis clearly deserves attention and statistical testing.
Beside the possible role of local big industrial ﬁrms as anchor tenants, the
literature has identiﬁed two key aspects of the local environment in high-tech
industries. Biotech ﬁrms are strongly dependent on both basic science and
venture or equity ﬁnancing. Let us ﬁrst review the knowledge issue, that is
both the existence of a strong local science base and, more generally, the fact
that ﬁrms enjoy knowledge spillovers. Since Jaﬀe et al. (1993), it is a broadly
accepted view that knowledge spillovers are essentially local, at least at the early
stages of development of the technology, because spatial proximity fosters the
transfer and acquisition of tacit (and complex) knowledge. It is thus natural to
assume that the existence of spillovers will attract ﬁrms to a given place and will
favorably inﬂuence their posterior performances. In a seminal paper, Audretsch
and Feldman (1996) show that the geographic concentration of innovation in
5Lerner et al. (2003) show that in periods in which biotech ﬁrms have diﬃculties to rise
equity capital, they are more likely to fund R&D through alliances with major corporations.
These alliances are signiﬁcantly less successful than the alliances formed when public market
ﬁnancing is easy. The authors’ interpretation of this result is that when public market ﬁnanc-
ing is diﬃcult, biotech ﬁr m sc e d em o r e( i nf a c tt o om a n y )c o n t r o lr i g h t st ot h eﬁnancing ﬁrm,
which reduces the eﬃciency of the outcome (Aghion and Tirole (1994)).
6For early discussions of vertical integration in the biotech sector, see also Pisano (1990,
1991).
7On the anchor tenant hypothesis (in medical imaging, neural networks and signal process-
ing), see also Agrawal and Cockburn (2003).
3US industrial sectors is explained by the importance of knowledge spillovers in
the sector, even after controlling for the concentration of production. Zucker
and al. (1998a) conﬁrms that the existence of a strong scientiﬁcb a s ea n d
more speciﬁcally the presence of star scientists explain both ﬁrms’ location and
their subsequent growth. Audretsch and Stephan (1996) examines whether the
collocation of ﬁrms and scientists indicates that the ﬁrms indeed form links
with local scientists. They show that it depends strongly on the role scientists
play in the ﬁrm. When knowledge transfers are central in the relation, as is
the case when scientists found ﬁrms, the propensity for the network to be local
is substantially increased. Zucker et al. (1998b) also sheds some light on the
mechanisms at work in localized knowledge spillovers. They consider Californian
biotech ﬁrms and show that while publications by local star scientists formally
linked to a ﬁrm increase this ﬁrm’s employment growth (between 1989 and 1994),
the publications by local stars not formally related to a ﬁr md o n ’ ti m p a c to ni t s
growth. They conclude that in the biotech sector, knowledge diﬀuses through
formal market relations rather than through the more informal diﬀusion process
generally pointed at when dealing with knowledge spillovers.
As regards the dependence to ﬁnancing, the literature suggests that the de-
velopment of local venture capital is important, even if its impact on ﬁrms’
growth is not clearly established. Powell et al. (2002) provide abundant illus-
tration of the collocation of venture capital and biotech ﬁrms in the US. They
also examine the evolution of the collocation pattern over time. However, they
don’t examine the impact of the presence of venture capital in the local environ-
ment on ﬁrms’ performances. Stuart and Sorenson (2003) shows that VC and
biotech ﬁrms’ collocation fosters new ﬁrms’ creation, but the local conditions
that promote new venture creation diﬀer from those that maximize the perfor-
mance of recently established companies. Concerning the time to IPO, startups
in close proximity to dense clusters of structurally equivalent high-technology
ﬁrms perform worse than otherwise comparable organizations in less concen-
trated areas. This suggests the existence of congestion costs in dense clusters.
The collocation of venture capital and biotech ﬁrms doesn’t impact on the time
to IPO.
In this paper, we explore the link between location and growth in the French
biotech industry between 1996 and 2002, distinguishing between two subperiods,
1996-1999 and 1999-2002.8 We estimate a baseline model in which we include
only size and age variables. Based on these estimations, we select the model best
suited for each of the two periods. A by-product of this analysis is that we test
for Gibrat’s law for French biotech ﬁrms. There is a huge literature on Gibrat’s
law and more generally on the link between size, age and growth. The classical
empirical references are Evans (1987a, 1987b), Dunne, Roberts and Samuelson
(1989) and Hall (1987). On the theoretical side, there are two main references,
Pakes and Eriksson (1998) and Jovanovic (1982). See Sutton (1997) for an
8Globerman et al. (2005) examine the same issue for Canadian information technology
ﬁrms between 1998 and 2001. They ﬁnd that the distance to Toronto has an impact on
the growth of ﬁrms’ turnover, while locational dummy variables have no impact. They also
analyze the survival of ﬁrms and ﬁnd no impact of localization.
4excellent survey on these issues. See also Geroski (1995). Since the publication
of these surveys, the ﬂow of papers on the topic continued and we don’t intend to
provide here a survey of this literature. To put it brieﬂy, it seems well established
that size and age have a negative inﬂuence on growth.9 Quite interestingly for
us, Almus and Nerlinger (2000) examine the link between size and growth for
young ﬁrms belonging to technology intensive branches of the West German
manufacturing sector between 1989 and 1994. Their results conﬁrm the negative
impact of size on growth. Furthermore, they ﬁnd no signiﬁcant diﬀerence in
the impact of size on growth between technology intensive and non-technology
intensive branches. This suggests that high-tech ﬁrms may be similar to more
traditional ﬁrms in this regard.10
In order to capture the impact of location on growth, we then introduce
dummy variables corresponding to locations in the models. We use three alter-
native sets of dummies. The ﬁrst set corresponds to administrative regions. This
is in line with the work on French ﬁrms by Autant-Bernard and al. (Autant-
Bernard and al. (2003)) and several U.S. studies, using the state level as the
unit of location (Audretsch and Feldman (1996), Prevezer (1995)).11 This set
of dummies is readily available and produces interesting results, but probably
captures more than the local eﬀects we want to focus on. There is a need to
narrow the geographic scope of the areas if we want to approximate science
districts. The second set of dummies is a ﬁrst attempt to do that. We in fact
characterize the ﬁrms based on their being or not in a urban unit in which a
genopole is operating.12 At least two studies report preliminary results (based
on small number of ﬁrms) for ﬁrm growth and survival in and out science parks
(Löfsten and Linderlöf (2002), Fergusson and Olofsson (2004)). The third set of
dummies is more reﬁned. We build clusters based on a hierarchical clustering
analysis and retain 15 clusters.13 The shape of clusters (in terms of geographic
spread in particular) is coherent with the notion one can have of a science dis-
trict as an agglomeration of science based ﬁrms, small or large, glued together
9T h e r ei sa l s os o m ew o r ko nt h ep e r s i s t e n c eo fg r o w t h .R e c e n t l y ,C o n g m i n ga n dL e e( 2 0 0 3 )
shows that sales growth of biotech ﬁrms over the 1995-1997 period is positively inﬂuenced by
sales growth between 1993 and 1995. We don’t test for such eﬀects in this paper. Our primary
focus in on the comparison of the two periods rather than on the persistence of growth from
one period to the other.
10While there is abundant literature on the link between size and growth in manufacturing
sectors, there are few studies on the link between size and growth in the services. In the only
study of services sectors we know, Audretsch et al. (2002) validate Gibrat’s law for a large
sample of Dutch ﬁrms in the hospitality industries. It is an open question whether this result
is valid for service ﬁrms operating in other sectors. In particular, some biotech ﬁrms provide
research services to other ﬁrms, but given the diﬀerence between hospitality activities (hotels,
...) and R&D services, it seems reasonable not to draw any conclusions from Audretsch et al.
(2002) for our purpose.
11For the USA, Zucker and al. (1998) use Functional Economic Areas as an alternative to
states.
12Similarly, DeCarolis and Deed (1999), e.g., use Metropolitan Statistical Areas for the
USA.
13Baik and Folta (2001) use a similar approach, although they are not very precise in the
description of the methodology used to build the clusters. Audretsch and Stephan (1996)
build geographic areas that are in general larger than a city but smaller than a state.
5by knowledge ﬂows. This approach is also in line with a recent study of indus-
trial clustering of Canadian biotechnology ﬁrms (Aharonson and al. (2004)). It
has the advantage not to rely on the assumption that each and every ﬁrm is in
ac l u s t e r .
We combine these diﬀerent approaches of location with two approaches of
growth (in fact two baseline models): one in which we regress ﬁrms’ growth
on the previously listed explanatory variables and one in which we explain the
probability that ﬁrms’ experience fast growth in the period. We distinguish
between two types of fast growing ﬁrms, gazelles and impalas. The estimations
of these diﬀerent models converge to a quite clear picture of the role of location
in ﬁrms’ growth in France over the 1996-2002 period.
The next section presents the context in which French biotech ﬁrms emerged
and grew in the period. Section 3 presents the data we use to run our estima-
tions. Section 4 presents the basic growth model. The estimations of this model
are in section 5. Section 6 and 7 are devoted to fast growth models. Section 8
concludes the paper and suggests directions for future work.
2 The context of French biotech ﬁrms’ develop-
ment
The creation of Dedicated Biotech Firms has started in France in the 1980’s.14
The Law on innovation, enacted 1999 July 12th, also called the Allegre Act, in-
troduced new possibilities of cooperation between the research world (research
institutions, universities, public labs...) and the ﬁrms’ world.15 Public re-
searchers are now given more incentives to participate to ﬁrms’ creations, while
public research laboratories and universities have created transfer and valoriza-
tion structures (e.g. France Innovation Scientiﬁque et Transfert for the CNRS),
etc. Venture capital dedicated to biotechnology was created at the same time.
In this section, we brieﬂy develop these diﬀerent aspects of the French biotech-
nology context.
2.1 The French biotech context in January 1999
At that time, the French public policy in favour of research and innovation is
fragmented. This fragmentation is due to a multi-actor and multilevel public
policy (Reiss, 2003). The so-called “Rapport Guillaume” (Guillaume (1998)) on
t h eF r e n c hi n n o v a t i o ns y s t e mh a ds h o w nt h a tt h ee ﬃciency of the massive R&D
14For more details on the French biotechnology industry and policy proﬁle, see Enzig (1999),
Senker (2001) and Reiss (2003).
15Loi n◦99-587 du 12 juillet 1999 sur l’innovation et la recherche, JOURNAL OFFI-
CIEL DE LA REPUBLIQUE FRANCAISE, 13 juillet 1999, n◦160, p.10396. Available
(by 13/02/03) at: <http://www.adminet.com/jo/19990713/MENX9800171L.html>.S e e
also Circulaire du 7 octobre 1999 relative à l’application de la loi n◦99-587 du 12 juil-
let 1999 sur l’innovation et la recherche concernant les coopérations des personnels de
recherche avec les entreprises. MENRT, p.15344-15350. Available (by 13/02/03) at:
<http://www.recherche.gouv.fr/technologie/mesur/innojo.htm>.
6budget eﬀort made by diﬀerent ministries was challenged by poor links between
the public and private sectors. The deﬁnition of large research programmes was
modiﬁed in the late 1990s : from a large ﬁrms orientation in the early 1990s
to a start-up creation and SMEs focus in the late 1990s (Enzig (1999) ; Senker
(2001)). No speciﬁc fund is dedicated to the biotech industry at that time.
From 1994 to 1998, the venture capitalists increased their investments in France
by 13% (see Table 22).
While the French biotechnology proﬁle regarding knowledge base indica-
tors (publications in biotechnology ﬁeld) is comparable with that of other large
countries like the UK or Germany, France is not a leading country regarding the
commercialisation of science (number of biotech companies or patent applica-
tions) over the 1994-2000 period (Reiss, 2003). During the 1990s, the process of
consolidation (mainly mergers) in agrochemical, pharmaceutical and seed com-
panies transformed the industrial environment of the emergent biotechnology
sector in France. 165 biotech ﬁrms were created between 1993 and 1999.
2.2 The evolution of the context since 1999
The Allegre Act introduced new possibilities of cooperation between the re-
search world (e.g., research institutes, universities, public lab) and the indus-
try.16 From that time, the institutional and legal context was more favorable to
ﬁrm creation in high tech sectors and to technological transfer from public to
private. New structures dedicated to biotechnology were designed: 5 Research
and Technological Innovation Networks (Réseaux de Recherche et d’Innovation
Technologique) regrouping public and private actors related to biotechnology
were created : GenHomme (2000, vegetal genomics and GMO) , Génoplante
(1999, genomics and proteomics for the human being), Technologies pour la
santé (2000, medical applications), and Alimentation références Europe (2001,
food). They received 130,9 MF of public funds in 2000. The Centres Régionaux
d’Innovation et de Transfert de Technologie (CRITT) were developed speciﬁ-
cally for the SMEs. The CRITT Bio-Industries in Midi-Pyrénées is dedicated
to Biotechnologies.
The Research Ministry has also participated, with regional and local au-
thorities, to the emergence of Bio-incubators and Genopoles. Bio-incubators
help founders at the initial stage of development of their biotech ﬁrms. The
bio-incubators are : Paris Biotech, Eurasanté in Lille, the Genopole of Evry,
Crealys in Lyon, Atlanpole in Nantes, Semia in Strasbourg, Emergys in Rennes,
Busi in Auvergne, and the incubators in Nîmes and Franche-Comté. Genopoles
16The law is composed of four parts. The ﬁrst part deals with the collaborations between
public researchers and ﬁrms. Researchers may be allowed to temporarily leave their job in
order to work in a ﬁrm (creation or not) that will valorize their work or to participate to that
ﬁr m ’ sc a p i t a lo rt ob e l o n gt oaﬁrm’s committee without leaving their job. The second part
is dedicated to relationships between ﬁrms and public research. It completes the 1982 and
1984 laws, by creating structures more adapted to high tech SME’s. In particular, incubators
may be developed. The third part aims at developing a favorable tax policy. The fourth part
concerns a speciﬁc legal structure for innovative ﬁrms. Further changes in the legal context
were introduced by the 2001 Law of Finances.
7have been selected by the Research Ministry for their activity in the ﬁeld of
t h eg e n o m ea n dp o s t - g e n o m ep r e s e n tal a r ge-scale biology project, an excellent
campus for training and research, a structured project for research promotion, a
high-level bioinformatics unit, a structured project for biotechnology company
creation. The genopoles are located around Evry, Lille, Strasbourg, Montpel-
lier, Toulouse, Marseilles-Nice, Lyon-Grenoble and Rennes-Nantes. Three sites
in Paris - the Institut Pasteur, the Montagne Sainte Geneviève group of labo-
ratories and the Center for Human Genomics of Paris V University - form the
"Ile de France" region genopole, with Evry as its ﬂagship site.17
Finally, ANVAR, the national agency for research valorization, has increased
its support to SMEs. Since 1999, it has been authorized to directly invest in
ﬁrms’ capital. Bioam, a venture capital fund dedicated to early-stage ﬁnancing
of biotech companies, was created in 2000. This fund has facilitated the ﬁrst
stage of development of biotech ﬁrms. It participates to the growing activity of
venture capital in the ﬁeld (their investments have grown by 34% from 1999 to
2003, as compared to 13% from 1994 to 1998, biotech being the ﬁrst industry of
investment since 2000 ; see Table 22). In 2000, no IPO was realized in France,
against 4 in the United-Kingdom and 8 in Germany. The ﬁnancial market is
not suﬃcient to support the growth of the French biotechnology industry.
The institutional and public research infrastructures evolution initiated by
the law on innovation in 1999 has contributed to reinforce research valorization
and ﬁrm creation in France. The interest for industrial property has also been
enhanced among public researchers, with the possibility to get ﬁnancial proﬁt
from their research results. Industrial applications have been encouraged by a
higher accessibility of the laboratories to venture capitalists or to co-funding.
The sale of technological services by laboratories has been encouraged too. The
venture capitalists have invested more funds in biotech during the 2000s than
the 1990s. Finally, whereas the national government was a key player during
the 1990s, regional and local authorities have been growing in importance more
recently, through their implication in bio-incubators and genopoles. Because of
the very signiﬁcant changes that took place in 1999, it seems relevant to split
the 1996-2002 period into two sub-periods, before and after 1999.
3D a t a d e s c r i p t i o n
3.1 The database
3.1.1 The identiﬁcation of biotech ﬁrms
We build the list of French biotech ﬁrms from 3 elements: the list of the GAEL
laboratory, which collects information on biotech ﬁrms since 1999, a list provided
by the French Research Ministry, which has also been following the biotech
17For more information on genopoles, see E.M.B.O. (2003) and Ernst&Young (2003). These
reports, as well as other elements of information, are available on the home page of the National
Genopoles Network at http://rng.cnrg.fr/?id=&origin=&plt=&lang=en.
8sector for several years, and the ﬁrms which reported in the 2000, 2001 or 2002
R&D surveys more than 30% of their R&D expenditures in the biotech ﬁeld.
Merging these 3 lists, we identify 709 ﬁrms which exist or have existed in the
period 1996-2002 and for which we have information on size for at least one
year.
3.1.2 The variables in the database
We collected individual ﬁnancial data on the ﬁrms in the sample for the 1996-
2002 period, mainly from the DIANE database. This database also provides the
employment for each year, the date of creation and the address of the ﬁrm. If
the ﬁrm has several plants, we localize it at the headquarter of the ﬁrm. We use
location information at the "communal" level, which allows us to build variables
based on more aggregated geographic levels.
3 . 2 T h es a m p l e su s e di nr e g r e s s i o n s
3.2.1 The two periods
As already explained, we distinguish in our sample two periods of three years:
the 1996-1999 period (sample 1) and the 1999-2002 period (sample 2). To
study the growth of ﬁr m sw en e e dt h es i z eo ft h eﬁrm (measured by annual
turnover) at the beginning and at the end of each period. This reduces our
samples to ﬁrms which exist at the beginning and the end of the period and for
which we have size information for both years. In particular, we exclude from
t h es a m p l et h o s eﬁrms that existed at the beginning of the period, but didn’t
survive until the end of the period. This creates a sample selection bias that
will be addressed in future work. This typically supposes to run type II Tobit
models (see Wooldridge (2002)).
3.2.2 Restrictions of samples
Our database includes large multisectorial ﬁrms which growth probably doesn’t
signiﬁcantly depend on their activity in the biotech sector. We exclude them
from the sample when estimating the models.18 A preliminary analysis of the
list of ﬁrms ranked by descending turnover suggests to exclude from the two
samples ﬁrms with more than 75 millions € of sales at the beginning of the
period. Using this threshold leads us to exclude two large dedicated biotech
ﬁrms that are subsidiaries of multinationals.
Table A shows that sample 2 is larger than sample 1. This reﬂects the
increase in the number of biotech ﬁrms over the 1996-2002 period.
18However, because they can be attractive for other biotech ﬁrms and more generally gen-
erate externalities for other biotech ﬁrms, we keep them to build our clusters (see below).
93.3 The samples description
3 . 3 . 1 S i z ea n da g ev a r i a b l e s
Tables B and C show the distribution of the variables in the two samples. The
age of ﬁrms is on average of 13 years, with 25 percent of ﬁrms older than 15 years.
These are mainly ﬁrms which existed before the emergence of new generation
biotechs and specialized in the biotech ﬁeld afterwards. The distributions of the
sales variables (Si,t and Si,t0) are very similar in Period1 & period2. Considering
growth, the median increases slightly between the ﬁrst and the second period,
from 33% to 38%. Fifty percent of ﬁrms increased their sales by more than 30%
over each period. The distribution of growth rates has a very large variance.
In particular, some ﬁrms have huge growth rates. Q90 is around 300% between
1996 and 1999 and the mean is even larger, at about 800%. It is probably
due to some ﬁrms (potentially very small ones) experiencing enormous growth
rates (possibly corresponding to modest absolute growth). For this reason, the
median is a better statistic in this case.
3.3.2 location variables
The regions There are 26 administrative regions in France (22 in the metropol-
itan area). Table D shows the distribution of ﬁrms between regions in both
samples. About 28% of French biotech ﬁrms were in Ile-de-France in the ﬁrst
period as compared to about 26% in the second period.19 The weight of the
ﬁrst region is very important but decreases slowly. The second region is Rhône-
Alpes with 11% of biotech ﬁrms in the ﬁrst period, rising to 13.5% in the second
period. Next in descending order, Alsace and PACA represent about 8% each
of biotech ﬁrms.
The genopoles Genopoles are science parks with a label from the French Min-
istry of Research. The label was created in 1999. They are now in a number of
eight. We build the genopole variable by considering the “urban units” (French
concept of city) which are at the hearth of the genopole: Paris, Lyon/Grenoble,
Marseilles/Nice, Lille, Strasbourg, Toulouse, Montpellier, Rennes/Nantes. This
is a bit rough. Clusters (see below) are more reﬁned measures of location.
All genopoles are in the ﬁrst regions in number of biotech ﬁrms. Only two
regions, Aquitaine and Auvergne, have no genopole, although they have a sig-
niﬁcant number of biotech ﬁrms.20 The distribution of ﬁrms between genopoles
in shown in table E.
The clusters We build 15 clusters by removing from the sample the com-
m u n e sw i t hl e s st h a n1 0b i o t e c hﬁrms in a 20 kilometers distance, and by
grouping the remaining communes into 15 classes. The classiﬁcation is given
19Ile-de-France is approximately the urban area around Paris. It is by far the biggest French
region in terms of economic importance and population.
20Auvergne has a so-called "biopole", the Clermont-Limagne science park, which didn’t
receive the genopole label.
10by a hierarchical clustering analysis based on the ﬂight kilometer distance be-
tween the ﬁrms. All ﬁrms are localized at the City Hall of the commune where
they have their headquarters. There are three clusters in Ile-de-France: Paris,
Evry and Nanterre. While the ﬁrst two clusters correspond to clearly identiﬁed
research institutions (see section 2), Nanterre appears probably more because
many ﬁrms have their headquarters in this area, including the French sub-
sidiaries of multinational ﬁrms. This should be kept in mind when analyzing
the results presented below. The distribution of ﬁrms between clusters is shown
in table F.
4 The basic model
In this section, we present the results of the estimation on our data of a basic
model of ﬁrm growth in which we don’t include location variables. In the follow-
ing sections, we augment the model to include location variables. At this stage,
we include only two explanatory variables in the model, namely the size and
the age of the ﬁrm at the beginning of the period. These are well established
determinants of ﬁrm growth that it is natural to include in this basic model.
Let us ﬁrst consider the following basic model:
(logSi,t0 − logSi,t)/(t0 − t)=α + β logSi,t + εi,t (1)
where t is the initial year and t0 is the ﬁnal year of the period and Si,t is ﬁrm
i’s size at date t. This is a standard model of ﬁrm growth. It is derived from
Si,t0 = Si,t [Gi,t]
t0−t eηi,t (2)
where Gi,t is the annual growth rate of ﬁrm i between year t and year t0.
Taking logarithms leads to
logSi,t0 =l o gSi,t +( t0 − t)logGi,t + ηi,t (3)
and
(logSi,t0 − logSi,t)/(t0 − t)=l o gGi,t + εi,t (4)
where εi,t = 1
t0−tηi,t.
Finally, taking
Gi,t = eα (Si,t)
β (5)
leads to (1).
114.1 The 1999/2002 period
Table 1(1) presents the estimation of equation (1) for the 1999-2002 period and
annual sales as a measure of size. Although the model explains only 5.5% of
the variance of sales’ growth, it is globally signiﬁcant at 1%. The impact of
initial size on growth is negative, signiﬁcant at 1%. This means that Gibrat’s
law of proportional eﬀect, which can be stated here as β =0 ,i sn o tv e r i ﬁed for
French biotech ﬁrms over the 1999-2002 period. Small ﬁrms grow faster than
large ﬁrms over the period.
T h er a t h e rl o wv a l u eo fR2 in this regression suggests that we should include
more variables in the model. A ﬁrst natural candidate is the age of the ﬁrm.
So, we now assume that:
Gi,t = eα (Si,t)
β (Ai,t)
γ (6)
where Ai,t is ﬁrm i’s age at date t,d e ﬁned as the diﬀerence between t and
t h ey e a ro fc r e a t i o no ft h eﬁrm. This leads to:
(logSi,t0 − logSi,t)/(t0 − t)=α + β logSi,t + γ logAi,t + εi,t (7)
As can be seen from table 1(2), the inclusion of age improves the ﬁto ft h e
model for the 1999-2002 period. Age is signiﬁcant at 1%, size at 5%, with a
negative impact of age, which is not surprising in view of the literature.
There is another fruitful way to extend the model. Indeed, the scatter plots
suggest that the link between initial sales and their subsequent growth is non-
linear, with a more negative slope for small ﬁrms than for larger ones. To put
it diﬀerently, it seems that the negative impact of size on growth is stronger for
small ﬁrms. This is reminiscent of a result found by Hart and Oulton (1996).
An estimation of (1) on the ﬁrms of the sales quartile of our sample (not re-
ported here) conﬁrms this. This leads us to introduce in the model powers of
the size variable as explanatory variables. It turns out that a second degree
polynomial provides a much better ﬁt than the basic model. Table 2(1) reports
the estimation of
(logSi,t0 − logSi,t)/(t0 − t)=α + β1 logSi,t + β2 (logSi,t)
2 + εi,t (8)
for the 1999-2002 period. In table 2(2), we report the estimation of the
extension of this model that includes age as an explanatory variable, namely:
(logSi,t0 − logSi,t)/(t0−t)=α+β1 logSi,t+β2 (logSi,t)
2+γ logAi,t+εi,t (9)
Introducing the age in the regression improves the ﬁt and doesn’t induce
dramatic changes in the values of the parameters or in their signiﬁcance. In
both models, logSales exhibits a negative coeﬃcient that is much stronger that
in the previous estimations. The square variable is signiﬁcant, with a positive
impact. We adopt the speciﬁcation in (9) in the next sections for the 1999/2002
period.
124.2 The 1996/1999 period
Estimating equation (1) for the 1996-1999 period conﬁrms the violation of
Gibrat’s law (table 3(1)). Note that the eﬀe c to fs i z eo ng r o w t hi ss t r o n g e r
(in absolute value) for this period and that the model exhibits a much better
ﬁt (as measured by R2). However, table 3(2) shows that for the growth of sales
between 1996-1999, age is not signiﬁcant, even at 10%. So, while the viola-
tion of Gibrat’s law is clear, it seems not to be pertinent to include age as an
explanatory variable in the model for this period.
As regards the introduction of powers of the log of sales, a third degree
polynomial clearly outperforms the second degree polynomial for the 1996-1999
period. Table 4 presents the estimation of









Size is a more decisive determinant of growth on this period than on the
1999/2002 period. Including age in the model doesn’t seem to be pertinent. So,
we use mainly equation (10) as a basis in the next sections for the 1996/1999
period.
5 The impact of location on growth
5.1 The 1999/2002 period
5.1.1 Administrative regions
A very simple way to introduce location in the model is to include dummy vari-
ables corresponding to the administrative region in which the ﬁrm is located.
There are 22 metropolitan regions in France, but only 12 of these have a signif-
icant number of biotech ﬁrms (that is, at least ten ﬁrms in the sample).21 So,
we consider that in these 12 regions, ﬁrms may beneﬁt from spill-overs while
in the 10 other regions they don’t. However, we include only 11 regional dum-
mies in the model, excluding reg31(Nord-Pas-de-Calais) for which the number
of ﬁrms in the sample used to estimate the model is too low.22 Note that in
9 regions there is a genopole.23 We estimate an extension of (9) including the
21This threshold, although arbitrary, seems reasonable. Baik and Folta (2001) use the same
threshold, introducing a distinction between minor clusters (less than 20 ﬁrms) and major
ones.
22We include only these dummy variables for which at least 10 observations take the value
"1". Table D shows that this is the case for reg31, but we include age in the model and we
don’t know the age of one of the ﬁrms located in Nord-Pas-de-Calais.
23One of the 8 genopoles covers two regions, Bretagne and Pays-de-la-Loire.
13dummy variables. Table 5 provides the results of this estimation. It turns out
that for the 1999-2002 period, only one dummy variable (reg93) is signiﬁcant,
at a 5% level (p-value equal to 0.0106), with a positive eﬀect, while others have
rather large p-values. This dummy corresponds to Provence-Alpes-Côte-d’Azur,
a region in southern France in which a genopole is functioning, mainly around
Marseilles and Nice-Sophia-Antipolis.
Regional dummy variables are very rough measures of locational eﬀects and
are probably a poor approximation for science districts. The type of externalities
intervening at the regional scale may be quite diﬀerent from the knowledge
externalities emphasized in the analysis of science districts. We estimated the
models with more sophisticated indicators of location.
5.1.2 Genopoles
In a ﬁrst attempt to capture science districts, we build dummy variables based
on the fact that the ﬁr mi sl o c a t e di nau r b a na r e at h a ti sp a r to fag e n o p o l e
or not. We estimated a model including the dummy variables corresponding to
5 genopoles: Paris, Lyon/Grenoble, Marseilles/Nice, Strasbourg and Toulouse.
There were to few ﬁrms in the other 3 genopoles in our sample to include the cor-
responding dummies in the model. For the 1999/2002 period, we found no sig-
niﬁcant inﬂuence of these variables on growth.24 In particular, while Provence-
Alpes-Côte-d’Azur was signiﬁcant as a region, the Marseilles/Nice genopole is
not. Either the forces at work in PACA are not localized (in Marseilles and/or
Nice) or they are and our variable doesn’t allow us to show it. The next sub-
section suggests that we are in the second situation.
5.1.3 Clusters
It turns out that the models in which location is described by cluster dummies
provide the most interesting results. Table 6(2) shows that being located in
Marseilles (cl11) has a positive, signiﬁcant (at a 10% level) impact on growth.
The eﬀects observed at a regional level persist at the local (cluster) level. Table
6(1) shows that, removing age from the regression, Nanterre (cl1) and Toulouse
(cl6) have a signiﬁcant impact (at a 10% level), this impact being negative in the
case of Toulouse. Since these eﬀects vanish when we include age in the model
(which improves the performances of the model), they probably reﬂect mainly
the distribution of ﬁrms’ ages in these two areas. We thus retain mainly table
6(2) and the Marseilles eﬀect for this period.
5.2 The 1996/1999 period
5.2.1 Administrative regions
Between 1996 and 1999 (table 7), Provence-Alpes-Côte-d’Azur is not signiﬁcant,
Rhône-Alpes is (at a 1% level) and, at a 5% level, Alsace is also. The diﬀer-
ence between the two periods is very clear. Note that the creation of genopoles
24The estimates are not reported here.
14started in 1999, so that our results suggest that the creation of genopoles, and
more generally the modiﬁcation of the environment in which biotech ﬁrms were
created and grew due to the so-called "Allegre" law, radically changed the rel-
ative performances of regions in terms of their ability to provide biotech ﬁrms
with an environment favorable to their growth.
5.2.2 Genopoles
For the 1996/1999 period (table 8), Lyon/Grenoble (gen2) is signiﬁcant at a
10% level which suggests that part of the eﬀects associated with being located
in Rhône-Alpes during this period are associated with being located either in
Lyon or in Grenoble.25
5.2.3 Clusters
Table 9(1) presents the results for the 1996/1999 period. Here, the only sig-
niﬁcant cluster dummy is Paris (cl3), with a negative impact (signiﬁcant at a
10% level) that is not due to the age distribution of ﬁr m si nt h i sa r e a ,a sc a n
be checked in table 9(2). In the "region" model, Ile-de-France has no impact on
growth. It must be kept in mind that Ile-de-France includes 3 clusters, namely
Nanterre, Evry and Paris. Distinguishing these three places is one of the good
things in the "cluster" model. To the contrary, Alsace as a region is signiﬁcant,
but Strasbourg, as a cluster, is not.26
Including age in the regression, Lyon becomes signiﬁc a n t . T h i si si nl i n e
with the fact that Rhône-Alpes has a positive impact on growth (see table 7),
but including age doesn’t improve the performances of the model, so we retain
mainly the Paris (negative) eﬀect. One interpretation of this negative eﬀect
is that ﬁrms located in Paris suﬀer from diseconomies of agglomeration to be
linked to high levels of congestion costs, strong local competition for localized
inputs and knowledge expropriation. In other words, the cluster would be in the
declining phase of its life cycle (see Pouder and Saint John (1996) and Baik and
Folta (2001)). This interpretation seems implausible for two reasons. Firstly,
Baik and Folta (2001) ﬁnd that U.S. biotech clusters entered the decline phase
after at least 20 years and the development of the French biotech industry dates
back only to the 80’s. One should then assume that this cluster entered the
declining phase particularly fast. Secondly, and more importantly, there is no
negative eﬀect of being located in Paris in the estimates on the next period
(1999/2002), which clearly challenges the "decline" hypothesis.
25Including age in the regression makes Lyon/Grenoble signiﬁcant at a 5% level and Stras-
bourg (gen5) at a 10%. We don’t report the estimation here, both to be in line with the other
sections and, more importantly, because including age in the regression doesn’t improve the
ﬁt. Recall however that Alsace was also found to be signiﬁcant in the "region" analysis.
26In fact, Strasbourg has a positive, signiﬁcant impact on the growth between 1996 and 1999
in models in which logSales3 is not included, regardless of the fact that logAge is included
or not. It is signiﬁcant at 10% in the model without age and at 5% in the model with age.
However, including the third degree term clearly improves the performances of the model, so
we don’t present these estimates.
155.3 Conclusion
Switching from the "region" model to the "cluster" model induces quite im-
portant changes in the results. There is however one result that is robust to
this change in explanatory variables. Biotech ﬁrms grew more in PACA and/or
Marseilles than in other locations between 1999 and 2002. Note that the ampli-
tude of the eﬀect is approximately the same in the "region" and the "cluster"
models. Furthermore, the "cluster" model allows us to distinguish between dif-
ferent areas within Ile-de-France and show that Paris is a location in which, for
the period 1996/1999, biotech ﬁrms grew slower than elsewhere.
6 The determinants of rapid growth
In this section, we use a diﬀerent approach of the determinants of growth in
general and the role of location in growth in particular.
6.1 The gazelle model
This section presents the rapid growth model. We distinguish between two types
of ﬁrms, those that experience a rapid growth over the period (at least 50%)
and the others. Fast growers are commonly named "gazelles" in the literature,
which refers to the fact that these animals run very fast. We build a dummy
variable, that is equal to one is the ﬁrm is a gazelle and zero otherwise, and put








We then estimate the following equation:
P(yi =1|xi)=Λ(x0
iβ) (13)
where Λ is the cdf of the standard logistic distribution, xi is the vector of
explanatory variables (for observation i)a n dβ is the vector of parameters of
the model. As for the study of growth, we take as explanatory variables the log
of sales (and powers of the log of sales), the log of age and locational dummy
variables (regions, genopoles, clusters). It turns out that introducing age in
the regression improves the ﬁt of the model, as would indeed the introduction
of any variable, but size is no more signiﬁcant, whereas it is signiﬁcant at a
1% level when age is not included in the model. As regards powers of the size
variable, the estimations clearly indicate that they should not be included in the
model. We thus adopt a speciﬁcation of the model with only size and locational
variables both for the 1996-1999 and the 1999-2002 period. Tables 10 and 11
present the estimates for the basic model including only size as an explanatory
variable.
166.2 The 1999/2002 period
6.2.1 Administrative regions
As in the growth case, location in the model is introduced by dummy variables
corresponding to the administrative region in which the ﬁrm is located. We con-
sider only the twelve regions where at least ten ﬁrms from the sample are present.
Table 12 provides the estimates. It turns out that for the 1999-2002 period, two
dummy variables, reg91 and reg93, are signiﬁcant at a 5 % level. One dummy
variable, reg73, is signiﬁcant at a 10% level. The dummy reg93 corresponds to
Provence-Alpes-Côte d’Azur and was already signiﬁcant in the growth model.
The dummy reg91 corresponds to Languedoc-Roussillon, in which a genopole
(Montpellier) is functioning since 2001. The location in Languedoc-Roussillon
was not signiﬁcant in the growth model. Similarly, Midi-Pyrénées (reg73) was
not signiﬁcant in the growth model. While PACA is a place where ﬁrms both
growth more and have a higher probability to experience fast growth, being
located in Languedoc-Roussillon or in Midi-Pyrénées has an impact only on the
probability of fast growth, while growth rates are not signiﬁcantly larger than
elsewhere.
6.2.2 Genopoles
Table 13 shows that there is only one out of our ﬁve genopole dummy variables
that is signiﬁcant. Being located in either Marseilles or Nice (in fact in the
urban area of one of these two cities) has a positive, signiﬁcant (at 5%) impact
on the probability of fast growth. It has no signiﬁcant impact on growth. While
Midi-Pyrénées has a positive impact on the probability of fast growth, being
located in Toulouse (gen6) is not signiﬁc a n t .W ec a n n o tt e s tt h ee ﬀect of being
located in Montpellier because there are too few ﬁrms in the Montpellier urban
area.
6.2.3 Clusters
Table 14 shows the estimates for the model including cluster dummies. Being
located in Nanterre (Cl1) has a positive, signiﬁcant impact on rapid growth at a
1 % level, while being located in Marseilles has a positive, signiﬁcant impact at a
10 % level. The eﬀects associated to Marseilles/PACA observed at the regional
and the genopole levels persist at the cluster level. Recall also the Marseilles
(as a cluster) has a positive impact on growth over this period. Furthermore,
because we distinguish three clusters in Ile-de-France, Nanterre can appear as
signiﬁcant while Ile-de-France, Paris (cl3 & gen1) and Evry (cl5) do not.
6.3 The 1996/1999 period
6.3.1 Administrative regions
Between 1996 and 1999 (see table 15), Alsace is the only region with a signiﬁcant
impact on grow (at a 10 % level). Firms in this region had a higher probability
17to experience fast growth. This conﬁrms the results of the growth models for
this period. This is all the more the case as Rhône-Alpes, also it is not signiﬁcant
at a 10% level, has a p-value very close to 10.
6.3.2 Genopoles
No genopole has a signiﬁcant inﬂuence on rapid growth. While Lyon/Grenoble
has an impact on growth, it has no impact on rapid growth. We don’t report
the estimates of this model.
6.3.3 Clusters
No signiﬁcant cluster variable. We don’t report the estimates of this model.
7I m p a l a s
In the previous section, we analyze the determinants of the probability that
a ﬁrm is a gazelle over the period. There are many species of gazelles with
quite diﬀerent characteristics. In particular, they diﬀer by their size. For exam-
ple, impalas are twice as big as springboks. In what follows, we use the term
"impala" to describe big fast-growers, while springboks will denote small fast-
growing ﬁrms. In the previous section, we don’t distinguish between impalas
and springboks. In this section, we focus on impalas. This is motivated by the
simple fact that a 50% growth of a ﬁrm with ten thousands euros of turnover has
very diﬀerent consequences as the same growth rate for a ﬁrm with ten millions
euros of turnover. In order to identify impalas, we modify the deﬁnition of the





Si,t Si,t0 >Q 75
0 otherwise
(14)
where Q75 is the third quartile of the distribution of
Si,t0−Si,t
Si,t Si,t0.T h i s
deﬁnition of impalas is based on the Birch Index, a combined measure of absolute
and rapid growth. The Birch index is commonly used when studying fast-
growing ﬁrms (Almus (2002)). Note that impalas are not necessarily gazelles as
deﬁned by (12).We then run estimations of the same type of models as in the
previous section, with the diﬀerence that we include the squared log of size and
the log of age as explanatory variables. The reason for this choice is that these
models provide a much better ﬁt than the model with only the log of size.27
The rest of the section is devoted to the presentation of these estimates.
27Alternatively, explaining rapid growth in Canadian biotechnology ﬁrms, Niosi deﬁnes
rapid-growth ﬁrms as ﬁrms that have grown of 50% and over of total employment and/or
sales between 1994-1998 and that have crossed the threshold of 25 employees and/or 2 million
dollars in sales (Niosi(2000,2003)).
187.1 The 1999/2002 period
7.1.1 Administrative regions
Two regional dummies have a positive impact signiﬁcant at 1% (see table 16).
These are PACA and Ile-de-France. While PACA is also signiﬁcant in the
gazelle model, Ile-de-France is not. This suggests that being located in Ile-de-
France is positive for the (fast) growth of relatively big ﬁrms, this eﬀect being
diluted in the gazelle model because small ﬁrms don’t experience fast growth
with a higher probability in Ile-de-France. Furthermore, at 10%, Aquitaine has
a positive impact on the probability to be an impala. Aquitaine has no impact in
the gazelle model. Conversely, Midi-Pyrénées and Languedoc-Roussillon, which
have an impact in the gazelle model, are not signiﬁcant in the impala model.
7.1.2 Genopoles
The genopoles model conﬁrms the signiﬁc a n c eo fI d Fi nt h ei m p a l am o d e l( s e e
table 17). Paris is the only genopole dummy that is signiﬁcant. Interestingly,
Marseilles-Nice (gen3) is not, while it is in the gazelle model. This result suggests
that Marseilles may well be a good place for springboks and Paris a good place
for impalas.
7.1.3 Clusters
The clusters model indicates that it is in fact Nanterre within Ile-de-France
that is favorable to the growth of impalas (see table 18). Recall that it is also
the result obtained in the gazelle model. As for genopoles, Marseilles is not
signiﬁcant in the impala model, while it is in the gazelle model. Note however
that the p-value associated to Marseilles is very close to 10%.
7.2 The 1996/1999 period
We don’t present separately the three models because they provide essentially
the same message (see tables 19 to 21). Two places increased the probability to
be an impala in this period, Rhône-Alpes (the region, the Lyon-Grenoble geno-
pole and the Lyon cluster) and Alsace (region, Strasbourg genopole, Strasbourg
cluster). This conﬁrms the results obtained from the growth and the gazelle
models. Furthermore, genopoles and clusters are signiﬁcant as well as regional
dummies, while only the last are signiﬁcant in gazelle models. This suggests
that the role of the local environment in the growth of gazelles is the same for
impalas and springboks over this period. This is a diﬀerence with the 1999/2002
period.
8C o n c l u s i o n
The analyses presented here lead to two main conclusions. Firstly, location
matters in the French biotech industry. More precisely, it has a signiﬁcant
19impact on ﬁrms’ growth over the two periods considered in this paper. An
interesting aspect of our results is that the locations that appear to be favorable
are diﬀerent before and after 1999. Alsace and Rhône-Alpes are better places
than others before 1999. Concerning Alsace, we can relate this to the fact
that Alsace is linked to the Biovalley Bioregio created in Germany in 1996 that
received a signiﬁcant amount of money between 1996 and 1999, while over the
same period, there was no comparable program in France.28 After 1999, it is
clearly Marseilles (and its region) and Nanterre (and Ile-de-France, but it is
less clear (see below)) that are better places for biotech ﬁrms to grow. We
suspect that this evolution is related to the emergence of new structures and
institutions to support biotech ﬁrms (incubators, genopoles, ...). Our results
suggest that Marseilles was particularly successful in the development of an
environment favorable to the growth of biotech ﬁrms, while being located in
Nanterre increases more speciﬁcally the probability of fast growth. However,
since we don’t characterize locations by variables (other than dummy variables),
it is not possible to say what aspect of a given location was favorable to ﬁrms’
growth. Introducing variables characterizing the local environment is the next
step. We use diﬀerent concepts to capture location, one of which is the "cluster"
level. Looking at clusters has the advantage to distinguish between diﬀerent
places in Ile-de-France. Nanterre turns out to be a favorable location after 1999
, while Paris and Evry don’t. Because of the "headquarters" eﬀect discussed
in section 3, it is not clear what sort of mechanisms explain the eﬀect of being
located in Nanterre on growth. This point will be further examined in future
work. An interesting point to note is that Nanterre is not signiﬁcant for the
1996-1999 period. So, if Nanterre is signiﬁcant because of a headquarters eﬀect,
which still has to be examined, it remains to understand why this eﬀect didn’t
play for the ﬁrst period considered in this paper. Our second main conclusion is
that size also matters. In violation of Gibrat’s law, the initial size of ﬁrms has a
(non-linear, negative for small ﬁrms) impact on their subsequent growth. This
is a stylized fact that is broadly documented in the literature. It is interesting to
see that size explains a much larger part of ﬁrms’ growth before 1999 than after.
Our results are not very sensitive to the speciﬁcation of the model. Regressions
explaining the rate of growth and logit models explaining the probability of fast
growth lead to roughly the same results. The most notable evolution is between
gazelle and impala models, Ile-de-France emerging only in the second type of
models.
28For more details about public support to biotechs in Germany, see Giesecke (2000), Krauss
and Stahlecker (2001), Prevezer (2001) and Zeller (2001).
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Number of ﬁrms 314 393
Si,t > 0 300 375
Si,t > 0 & Si,t0 > 0 296 368
Notations: Si,t is ﬁrms i’s sales at time t (beginning of the period) and Si,t0
ﬁrm i’s sales at time t’ (end of the period).
Table B: Distribution of age in the samples
1996-1999 (Sample 1) 1999-2002 (Sample 2)
All Si,t > 0
Si,t > 0
& Si,t0 > 0 All Si,t > 0
Si,t > 0
& Si,t0 > 0
Number of ﬁrms 314 300 296 393 375 368
A g ea tt i m et( y e a r s )
Mean 13.3 13.4 13.6 12.7 13.0 13.2
Q10 2 2 2 1 1 1
Q25 4 4 4 4 4 4
Q50 7 7 7 8 8 8
Q75 16 16 16.5 15 15 15
Q90 35 35 35 27 27 28
26Table C: Distribution of size variables in the samples
1996-1999 (Sample 1) 1999-2002 (Sample 2)
All Si,t > 0 Si,t > 0 & Si,t0 > 0 All Si,t > 0 Si,t > 0 & Si,t0 > 0
Number of ﬁrms 314 300 296 393 375 368
Si,t (M€)
Mean 6.6 6.9 7.0 6.4 6.7 6.8
Q10 0.06 0.10 0.11 0.05 0.10 0.10
Q25 0.3 0.3 0.4 0.3 0.3 0.4
Q50 1.3 1.4 1.5 1.2 1.5 1.5
Q75 5.9 6.9 7.0 6.2 6.5 6.6
Q90 18.1 18.2 18.3 19.0 20.2 20.3
Si,t0 (M€)
Mean 12.8 11.9 12.0 9.9 10.3 10.6
Q10 0.14 0.19 0.21 0.07 0.12 0.15
Q25 0.5 0.6 0.6 0.4 0.5 0.5
Q50 2.0 2.3 2.3 1.9 2.1 2.3
Q75 10.2 10.3 10.4 8.7 9.1 9.2
Q90 25.9 26.2 26.5 27.6 29.8 30.0
(Si,t0 − Si,t)/Si,t
Mean 7.78 7.9 1.41 1.45
Q10 -0.24 -0.20 -0.36 -0.28
Q25 0.07 0.07 0.06 0.08
Q50 0.33 0.34 0.38 0.40
Q75 0.90 0.93 0.96 0.99
Q90 2.90 2.92 1.94 1.95
27Table D: Distribution of ﬁrms between regions
Variable 1996-1999 (Sample 1)
All Si,t > 0 Si,t > 0 & Si,t0 > 0
Number of ﬁrms 314 300 296
Ile-de-France reg11 87 83 82
Rhône-Alpes reg82 35 32 31
Alsace reg42 24 24 24
PACA reg93 25 23 23
Aquitaine reg72 19 19 19
Bretagne reg53 17 17 17
Midi-Pyrénées reg73 17 16 16
Pays-de-la-Loire reg52 15 15 15
Auvergne reg83 11 9 9
Languedoc-Roussillon reg91 9 9 9
Nord-Pas-de-Calais reg31 9 9 7
Centre reg24 8 8 8
Other regions 38 36 36
Variable 1999-2002 (Sample 2)
All Si,t > 0 Si,t > 0 & Si,t0 > 0
Number of ﬁrms 393 375 368
Ile-de-France reg11 101 95 89
Rhône-Alpes reg82 53 50 50
Alsace reg42 29 28 28
PACA reg93 31 31 31
Aquitaine reg72 20 19 19
Bretagne reg53 22 21 21
Midi-Pyrénées reg73 19 18 18
Pays-de-la-Loire reg52 20 20 20
Auvergne reg83 18 17 17
Languedoc-Roussillon reg91 15 14 14
Nord-Pas-de-Calais reg31 12 10 10
Centre reg24 12 12 11
Other regions 41 40 40
28Table E: Distribution of ﬁrms between genopoles
Variable 1996-1999 (Sample 1)
All Si,t > 0 Si,t > 0 & Si,t0 > 0
Number of ﬁrms 314 300 296
Paris gen1 79 75 74
Lyon/Grenoble gen2 28 25 24
Marseilles/Nice gen3 16 14 14
Strasbourg gen5 14 14 14
Toulouse gen6 12 11 11
Rennes/Nantes gen8 7 7 7
Lille gen4 5 5 3
Montpellier gen7 2 2 2
Not in genopole 151 147 147
Variable 1999-2002 (Sample 2)
All Si,t > 0 Si,t > 0 & Si,t0 > 0
Number of ﬁrms 393 375 368
Paris gen1 93 87 81
Lyon/Grenoble gen2 43 40 40
Marseilles/Nice gen3 23 23 23
Strasbourg gen5 18 17 17
Toulouse gen6 15 14 14
Rennes/Nantes gen8 10 10 10
Lille gen4 6 4 4
Montpellier gen7 5 4 4
Not in genopole 180 176 175
29Table F: Distribution of ﬁrms between clusters
Variable 1996-1999 (Sample 1)
All Si,t > 0 Si,t > 0 & Si,t0 > 0
Number of ﬁrms 314 300 296
Paris cl3 54 50 49
Lyon cl2 25 22 21
Nanterre cl1 13 13 13
Strasbourg cl9 15 15 15
Evry cl5 13 13 13
Toulouse cl4 12 11 11
Bordeaux cl10 13 13 13
Clermont cl6 9 8 8
Marseilles cl11 8 7 7
Antibes 6 5 5
Lille 5 5 3
Nantes cl12 5 5 5
Rennes 5 5 5
Angers 4 4 4
Montpellier 3 3 3
Not in cluster 124 121 121
Variable 1999-2002 (Sample 2)
All Si,t > 0 Si,t > 0 & Si,t0 > 0
Number of ﬁrms 393 375 368
Paris cl3 60 55 50
Lyon cl2 39 36 36
Nanterre cl1 17 16 16
Strasbourg cl9 20 19 19
Evry cl5 16 16 15
Toulouse cl4 16 15 15
Bordeaux cl10 14 13 13
Clermont cl6 12 11 11
Marseilles cl11 11 11 11
Antibes 7 7 7
Lille 6 4 4
Nantes cl12 8 8 8
Rennes 5 5 5
Angers 6 6 6
Montpellier 6 5 5
Not in cluster 150 148 147



















Figures in parentheses are standard errors.
∗ signiﬁcant at 1%, ∗∗ signiﬁcant at 5%, ∗∗∗ signiﬁcant at 10%.

























Figures in parentheses are standard errors.
∗ signiﬁcant at 1%.



















Figures in parentheses are standard errors.
∗ signiﬁcant at 1%, ∗∗ signiﬁcant at 5%, ∗∗∗ signiﬁcant at 10%.






























Figures in parentheses are standard errors.
∗ signiﬁcant at 1%, ∗∗ signiﬁcant at 5%.



















































Figures in parentheses are standard errors.
∗ signiﬁcant at 1%, ∗∗ signiﬁcant at 5%.









































































Figures in parentheses are standard errors.
∗ signiﬁcant at 1%, ∗∗ signiﬁcant at 5%, ∗∗∗ signiﬁcant at 10.










































Figures in parentheses are standard errors.
∗ signiﬁcant at 1%, ∗∗ signiﬁcant at 5%.





































































































Figures in parentheses are standard errors.
∗ signiﬁcant at 1%, ∗∗ signiﬁcant at 5%, ∗∗∗ signiﬁcant at 10.



































































39Table 13: Determinants of 1999-2002 rapid growth (genopoles)


























Figures in parentheses are standard errors.
∗ signiﬁcant at 1%, ∗∗ signiﬁcant at 5%, ∗∗∗ signiﬁcant at 10%.
40Table 14: Determinants of 1999-2002 rapid growth (clusters)























































































































43Table 17: Impalas, 1999-2002 (genopoles)
































Figures in parentheses are standard errors.
∗ signiﬁcant at 1%, ∗∗ signiﬁcant at 5%, ∗∗∗ signiﬁcant at 10%.
44Table 18: Impalas, 1999-2002(clusters)

















































































46Table 20: Impalas, 1996-1999 (genopoles)





























Figures in parentheses are standard errors.
∗ signiﬁcant at 1%, ∗∗ signiﬁcant at 5%, ∗∗∗ signiﬁcant at 10%.
47Table 21: Impalas, 1996-1999 (clusters)



































48Table 22: Venture capital investment in France (1992-2003)
Year 1992 1993 1994 1995 1996 1997
Total amount (M€) 1011 914 1096 751 876 1259
Year 1998 1999 2000 2001 2002 2003
Total amount (M€) 1788 2816 5304 3287 5851 3643
Source: AFIC
49